Trish Simner

Medicine & Life Sciences

1. Carbapenems 100%
2. carbapenemase 84%
3. cefiderocol 81%
4. Carbapenem-Resistant Enterobacteriaceae 48%
5. Klebsiella pneumoniae 33%
6. ceftazidime drug combination avibactam 31%
7. Pseudomonas aeruginosa 29%
8. Microbiology 27%
9. High-Throughput Nucleotide Sequencing 25%
10. Metagenomics 25%
11. Whole Genome Sequencing 24%
12. Bacillus 24%
13. Plasmids 24%
14. Lactams 24%
15. Escherichia coli 23%
16. Genes 23%
17. Colistin 23%
18. Communicable Diseases 18%
19. Enterobacteriaceae 18%
20. Mycobacterium 18%
21. Infections 17%
22. Anti-Bacterial Agents 17%
23. Tazobactam Drug Combination Piperacillin 16%
24. Agar 16%
25. Klebsiella Infections 15%
26. SARS Virus 14%
27. Bacteremia 14%
28. Nanopores 13%
29. tazobactam drug combination ceftolozane 13%
30. Molecular Epidemiology 12%
31. Electrospray Ionization Mass Spectrometry 12%
32. Mycobacterium tuberculosis 11%
33. Blood Culture 11%
34. Enterobacteriaceae Infections 11%
35. Nanopore Sequencing 11%
36. Cephalosporins 10%
37. Acinetobacter baumannii 10%
38. Technology 10%
39. Edetic Acid 9%
40. Aztreonam 9%
41. Polymerase Chain Reaction 9%
42. Canada 9%
43. United States Food and Drug Administration 9%
44. Tenosynovitis 9%
45. Microbial Sensitivity Tests 9%
46. Fever of Unknown Origin 9%
47. Infection Control 9%
48. Pseudomonas Infections 9%
49. Siderophores 8%
50. Sulfamethoxazole Drug Combination Trimethoprim 8%